Related references
Note: Only part of the references are listed.Access to innovative oncology medicines in Europe
L. Bergmann et al.
ANNALS OF ONCOLOGY (2016)
The changing model of big pharma: impact of key trends
Ajay Gautam et al.
DRUG DISCOVERY TODAY (2016)
Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
Sabine Vogler et al.
LANCET ONCOLOGY (2016)
Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations
Ernst R. Berndt et al.
HEALTH AFFAIRS (2015)
Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development
Bengt Jonsson
MOLECULAR ONCOLOGY (2015)
Market access of cancer drugs in European countries: improving resource allocation
Kim Pauwels et al.
TARGETED ONCOLOGY (2014)
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Camille Abboud et al.
BLOOD (2013)
Technology Assessment for New Oncology Drugs
Bengt Jonsson
CLINICAL CANCER RESEARCH (2013)
SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE-BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS-SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN
Warren G. Linley et al.
HEALTH ECONOMICS (2013)
HTA AND VALUE - AN INDUSTRY PERSPECTIVE
Andreas Fibig
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2013)
Assessing the Added Value of Health Technologies: Reconciling Different Perspectives
Michael Drummond et al.
VALUE IN HEALTH (2013)
Differences in external price referencing in Europe-A descriptive overview
Christine Leopold et al.
HEALTH POLICY (2012)
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective
U. Tirelli et al.
ANNALS OF ONCOLOGY (2009)
Does it matter who you are or what you gain? An experimental study of preferences for resource allocation
DLB Schwappach
HEALTH ECONOMICS (2003)
QALY-maximisation and public preferences: results from a general population survey
S Bryan et al.
HEALTH ECONOMICS (2002)
Efficacy, safety, and cost of new anticancer drugs
S Garattini et al.
BMJ-BRITISH MEDICAL JOURNAL (2002)
Share Paper
